Details

MIPS - Quality Measures - Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer

Quality Measures
Category QUALITY
Description Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH [gonadotropin-releasing hormone] agonist or antagonist)
eMeasure ID
First Performance Year 2017
Last Performance Year
Metric Type Single Performance Rate
National Quality Strategy Domain ECC
Measure Type Process
eMeasure UUID
NQF eMeasure ID
NQF ID 0390
Is High Priority?
Is Inverse?
Overall Algorithm
Primary Steward American Urological Association Education and Research
Submission Methods Registry
Eligibility Options
Performance Options
Is Risk Adjusted?
Vendor ID
Is Registry Measure?
Registry Measure Spec https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_104_Registry.pdf
Web Interface Measure Spec
Claims Measure Spec

Back to List